BOTHELL, Wash. and TORRANCE, Calif., March 26, 2015
/PRNewswire/ -- PharmaIN Corporation and the PolyPeptide Group
announced today that they have entered into an agreement under
which PolyPeptide will manufacture PharmaIN's Protected Graft
Co-Polymer (PGC™).
Under the terms of the agreement, PolyPeptide will develop a
large-scale GMP manufacturing process for PGC, which it will
provide to PharmaIN for addition of the pharmaceutical payload.
"Manufacturing PGC marks a significant step in diversifying the
range of products manufactured by the PolyPeptide Group," said
Jane Salik, CEO of the PolyPeptide
Group. "and is fully aligned with our commitment to support
technologies that improve the delivery of peptide
therapeutics."
"We are delighted to advance PGC to clinical grade large-scale
manufacturing to support internal and our corporate
partners' products pipelines," said Elijah Bolotin, CEO of PharmaIN. "and
collaborate with PolyPeptide, a world class peptide
manufacturer."
PGC is an injectable delivery system which provides the benefits
of PEGylation for peptides and proteins, without chemical
modification of the drug payload. The PGC backbone is a
polyamino acid, typically poly-L-lysine, to which short MPEG chains
and a binding moiety are attached. In a separate procedure, the
payload is attached non-covalently to binding
moiety.
PGC offers extended drug release, enhanced solubility and
stability, and passive targeting to inflamed, infected and
cancerous tissue. By virtue of its affinity binding mechanism, PGC
creates an equilibrium system between bound and free drug in the
bloodstream and interstitial space.
About The PolyPeptide Group: The PolyPeptide Group is a
contract manufacturing organization for peptides and peptide
related molecules. The Group is one of the world's largest
independent contract manufacturers of therapeutic peptides for the
cosmetic, pharmaceutical and veterinary markets employing more than
500 people at six manufacturing sites located in France, India, Scandinavia and the USA. For additional information about the
company, please visit www.polypeptide.com.
About PharmaIN: PharmaIN is a development stage
biopharmaceutical company located in Bothell, WA, and focused on enabling and
improving injectable therapeutics based on its patented and
proprietary drug delivery technology platform, Protected Graft
Copolymer (PGC™). For additional information about PharmaIN, please
visit www.pharmain.com.
PolyPeptide
Contact:
Trishul Shah,
MS
Associate Director
Business Development
trishul.shah@polypeptide.com
310-782-3569
|
PharmaIN
Contact:
Eli Sonkin
Finance and Operations
esonkin@pharmain.com
206-568-1450
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/polypeptide-group-to-manufacture-protected-graft-copolymer-pgc-for-pharmain-300056909.html
SOURCE PolyPeptide Group